Article Text

PDF
Extended report
Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial
  1. T W Jensen1,
  2. M S Hansen2,3,
  3. K Hørslev-Petersen4,
  4. L Hyldstrup1,
  5. B Abrahamsen5,
  6. B Langdahl6,
  7. B Zerahn7,
  8. J Pødenphant2,
  9. K Stengaard-Petersen8,
  10. P Junker9,
  11. M Østergaard10,11,
  12. T Lottenburger4,
  13. T Ellingsen8,
  14. L S Andersen2,
  15. I Hansen8,
  16. H Skjødt10,
  17. J K Pedersen4,
  18. U B Lauridsen10,
  19. A J Svendsen9,
  20. U Tarp8,
  21. H Lindegaard9,
  22. Anne Grethe Jurik12,
  23. Aage Vestergaard13,
  24. M L Hetland10,11,
  25. the Cimestra study group
  1. 1Department of Endocrinology, Copenhagen University Hospital, Hvidovre, Denmark
  2. 2Department of Rheumatology, Copenhagen University Hospital, Gentofte, Denmark
  3. 3Reuma Klinik Roskilde, Roskilde, Denmark
  4. 4Department of Rheumatology, Gigthospitalet, University of Southern Denmark, Gråsten, Denmark
  5. 5Department of Endocrinology, Copenhagen University Hospital, Gentofte, Denmark
  6. 6Department of Endocrinology and Internal Medicine THG, Aarhus University Hospital, Aarhus, Denmark
  7. 7Department of Clinical Physiology, Copenhagen University Hospital, Herlev, Denmark
  8. 8Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
  9. 9Department of Rheumatology, Odense University Hospital, Odense, Denmark
  10. 10Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup, Denmark
  11. 11Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  12. 12Department of Radiology, Aarhus University Hospital, Aarhus, Denmark
  13. 13Department of Radiology, Copenhagen University Hospital, Hvidovre, Denmark
  1. Correspondence to Dr Trine W Jensen, Department of Endocrinology 541, Copenhagen University Hospital, Hvidovre, Kettegaard Allé 30, Hvidovre DK 2650, Denmark; twj{at}dadlnet.dk

Abstract

Objectives The aims of this study were to investigate the influence of alendronate and intra-articular betamethasone treatment on bone mineral density (BMD) changes in hand, lumbar spine and femoral neck during 1 year of a treat-to-target study (Cyclosporine, Methotrexate, Steroid in RA (CIMESTRA)).

Patients and methods A hundred and sixty patients with early, active rheumatoid arthritis (RA) received methotrexate, intra-articular betamethasone and ciclosporin /placebo-ciclosporin. Patients with Z-score ≤0 also started alendronate 10 mg/day. BMD of the hand (digital x-ray radiogrammetry (DXR-BMDhand)), BMD of lumbar spine and femoral neck (dual x-ray absorptiometry (DXA-BMDlumbar spine and DXA-BMDfemoral neck)) and x-rays of hands, wrists and forefeet (modified Sharp-van der Heijde score) were measured at baseline and 1 year, with complete data available in 107 patients.

Results The change in BMD in hand, lumbar spine and femoral neck was negatively associated with the dose of intra-articular betamethasone (p<0.01 for all), but the bone loss in hand was modest and in the axial skeleton comparable with that of healthy individuals. Alendronate did not influence changes in DXR-BMDhand, which averaged −2.8%, whereas significant changes were observed in DXA-BMDlumbar spine and DXA-BMDfemoral neck in alendronate-treated patients (1.8% and 0.8%) compared with untreated patients (–1.8% and –2.2%) (p<0.01 and 0.02). Alendronate did not affect the radiographic progression (alendronate-treated patients: 0 (range 0–19), non-alendronate: 0 (0–18)).

Conclusions In early active RA, intra-articular betamethasone injections added to disease-modifying antirheumatic drug (DMARD) treatment led to minimal loss of hip and lumbar BMD, and the loss could be prevented by treatment with alendronate. Alendronate treatment did not affect radiographic progression.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.